Regulatory Challenges for the Wireless Health Industry Kathy Chester, Sr. V.P., Regulatory Affairs & Quality Assurance St. Jude Medical Cardiac Rhythm.

Slides:



Advertisements
Similar presentations
1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Advertisements

Medical Device Software Development
BME-IDEA Workshop, September 28, 2005
Testing Medical Devices A Brief Overview © 2005 Max Cortner. Copying and distribution of this document is permitted in any medium, provided this notice.
Regulatory Pathway for Platform Technologies
Strengthening the Medical Device Clinical Trial Enterprise
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Ensuring Patient Safety in Wireless Medical Device Networks Presented by: Eric Flickner Chris Hoffman.
1 Certification Chapter 14, Storey. 2 Topics  What is certification?  Various forms of certification  The process of system certification (the planning.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Good Clinical Practice GCP
Stages of drug development
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Challenges to Indian Multinational Cos. P. M. Kelkar 18 th March, 2006 Thorale Bajirao Peshwe Sabhagruha, Thane.
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.
Legal Issues Impacting Clinical Trials Medical Device Clinical Trials Update June 19, 2009.
Regulatory Problems Moderators: Eugene Chen and Michael Kochman, MD.
Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Understanding the Pre-IDE Program: FDA Perspective
Development and Regulation of Medical Products (MEDR-101)
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
The Impact of Regulations on Medical Device Design Richard C. Fries, PE, CRE Manager, Reliability Engineering Datex-Ohmeda Madison, Wisconsin.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
June 23, 2005Abiomed, H DRAFT. CIRCULATORY SUPPORT DEVICES PANEL Thursday, June 23, 2005 Abiomed, Inc. Abiocor® Implantable Replacement Heart HDE.
September 9, 2002, Circulatory System Devices Panel Meeting FDA Lead Reviewer Summary W.L. GORE & Associates EXCLUDER Bifurcated Endoprosthesis A. Doyle.
Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
Company LOGO. Company LOGO PE, PMP, PgMP, PME, MCT, PRINCE2 Practitioner.
Acceptance test of medical devices The good test report November 2013 Bjarne Månsson.
NMBP : Cross-cutting KETs for diagnostics at the point-of-care co-funded by LEIT-NMBP (DG RTD) and LEIT-ICT (DG CONNECT) Opening 20 Sep 2016 Closing.
An Brief Overview – Medtronic Wireless Medical Applications Prepared for: U.S. Federal Communications Commission U.S. Food and Drug Administration Public.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Medical Device Software Development
Regulatory Updates Health Sciences Authority Singapore
Analysis of Current Maturity Models and Standards
Premarket Notification 510(k) process
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
FDA’s IDE Decisions and Communications
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
National Immunization Conference April 19, 2010
Bioabsorbable DES and Biodegradable Polymers – FDA View
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Regulatory Synergies in Device Innovation
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Early Feasibility in the USA –An Academic View
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Medical Device Design and Development
FDA Perspective Marco Cannella, PhD Senior Lead Reviewer
NEW MDR Regulatory Context. NEW MDR Regulatory Context.
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Role of KMLTTB in HIV POC implementation
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Regulatory Challenges for the Wireless Health Industry Kathy Chester, Sr. V.P., Regulatory Affairs & Quality Assurance St. Jude Medical Cardiac Rhythm Management Division 1

Good News & Bad News  Good News  FDA stating in their strategic plan “mission critical” areas of applied research – wireless healthcare devices  The Council on Medical Device Innovation - identified areas of unmet public health need that could be addressed with medical products. The five areas identified in 2010 included two settings, wireless health care and home use of devices, and three medical targets, diabetes, spinal cord injury, and cancer.  FDA and FCC are working together to bring forward innovative wireless technologies for healthcare faster  Patents covering wireless aspects of medical technology are growing at a much faster rate than other device patents and make up 31% of the total. 2

Good News & Bad News  Bad News  Cutting edge wireless devices may be so novel that there may be no prior similar device(s) to base your approval pathway on  The level of evidence FDA wants for wireless devices is higher since they believe wireless is inherently less reliable than wired communication  Wireless Monitors: FDA believes diagnostic data is dangerous! They want to know: What are you monitoring/measuring, how often, and most importantly what will the user do with the information? You must prove that the information being provided will not be mis- used (i.e., leads to inappropriate actions) and that it provides clinical benefit  Therapeutic devices: The bar is even higher 3

FDA Paradigm for Diagnostic Devices  Relies heavily on intended use and claims being sought  “Functional” (e.g., “measures temperature”) – Inaccurate information causes small risk to patients… …can be counterbalanced by small benefits  “Diagnostic” (e.g., predicts rupture risk”) – Misdiagnosis causes greater risk to patients… …needs to be counterbalanced by large benefit 4 RisksBenefits

New Medical Technology Development Lifecycle 5 ConceptDevelopment / Pre-Clinical Testing Clinical Trials Medical Device Regulatory Submissions Market Release Proof of Concept Regulation begins and continues Clinical Trial Design FDA negotiations Radio Frequency Registrations

Typical Types of Product Pre-Clinical Testing  Component verification  Electrical parameter testing  Software validation  System integration testing  Environmental testing  Electromagnetic compatibility testing  Biocompatibility testing  Packaging verification  Sterilization validation  Human factors/usability testing  Animal studies 6

Unique Wireless Design Challenges  Beyond standard safety & effectiveness considerations, FDA has additional concerns for wireless devices, including:  Wireless coexistence  Wireless Performance  Data Integrity  Security  Electromagnetic compatibility (EMC)  Since these issues affect all stages of the product life cycle, FDA recommends they be considered in:  design requirements  design verification and validation  risk management processes and procedures 7

Design Challenges  Wireless reliability of communication  Connections lost without warning, failure to establish connections, or even slight degradation of service/signal can have serious consequences.  FDA especially concerned for devices having: wireless transmission of critical medical device alarms continuous physiological waveform data real-time control of therapeutic medical devices (such as wireless footswitches) time-critical medical telemetry (such as for real-time patient waveforms and alarms) wireless control of therapeutic devices. 8

9

Radio Frequency Device Registration Challenges  Requirements differ between countries: less harmonization  Some countries accept testing performed for US/FCC and Europe/ETSI EN  Some require additional ”in-country” testing and certification  Some require model specific certification  Some require RF approval prior to medical device registration, others accept parallel paths  Each region has-  different design update handling procedures  different user’s manual and labeling requirements for country specific symbols and warnings  Varying approval times for Telecommunications Authority approvals, from a few weeks up to 4 months

Wireless Implantable Monitor Examples  CardioMems Abdominal Aortic Anerysm (AAA) sensor  Intended for measuring intrasac pressure during and upon completion of endovascular procedures  510(k) cleared with no human clinical studies  Pulmonary Artery Pressure (PAP) Sensor 1  Same sensor as above placed in different location  Intended use – Reduce heart failure hospitalizations by measuring PAP  Original PMA, 500+ patient IDE human clinical trial to establish safety (adverse events) and effectiveness (reduction in heart failure hospitalizations) 1 CAUTION - Investigational device. Limited by federal law to investigational use. 11

Regulatory Strategies  Do your homework – find out what other products are approved/cleared that you can leverage as examples or predicates (FDA website, company websites, medical journals, clinicaltrials.gov, etc.)  Design and test to internationally recognized standards whenever possible  Talk to FDA early and often to propose indications for use and pre-clinical test strategies and to determine regulatory path [510(k), IDE, PMA]  Build in time in the schedule to negotiate the clinical trial design and endpoints with FDA  Consider OUS human feasibility studies 12

Regulatory Strategies (cont.)  Plan for EU market release (CE Mark) first  Consider going to market first with a simple application of the technology or limited intended use (e.g., discrete measurements in a healthcare setting versus continuous monitoring at home).  Benefits Get to market faster Generate revenue sooner Gain clinical/user experience before proceeding with more complex or higher risk applications Build relationship and trust while educating the regulatory agencies on the technology

14 Thank You